Likewise, increased expression of Ras guanyl nucleotide-releasing protein 2, RASGRP2, was associated with an increased risk for development of de novo AML and MDS (OR = 4.05; 95% CI, 1.84-8.91, Pmeta = 5 × 10–4) (Figure 4). The gene discussed is RASGRP2; the disease is myelodysplastic syndrome.